HUP0004363A2 - Miltefosint tartalmazó orális szilárd gyógyszerkészítmények leishmaniasis kezelésére - Google Patents

Miltefosint tartalmazó orális szilárd gyógyszerkészítmények leishmaniasis kezelésére

Info

Publication number
HUP0004363A2
HUP0004363A2 HU0004363A HUP0004363A HUP0004363A2 HU P0004363 A2 HUP0004363 A2 HU P0004363A2 HU 0004363 A HU0004363 A HU 0004363A HU P0004363 A HUP0004363 A HU P0004363A HU P0004363 A2 HUP0004363 A2 HU P0004363A2
Authority
HU
Hungary
Prior art keywords
leishmaniasis
treatment
agent
solid pharmaceutical
pharmaceutical compositions
Prior art date
Application number
HU0004363A
Other languages
English (en)
Inventor
Jürgen Engel
Peter Hilgard
Thomas Klenner
Eckhard Milsmann
Werner Sarlikiotis
Dieter Sauerbier
Original Assignee
Asta Medica Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag. filed Critical Asta Medica Ag.
Publication of HUP0004363A2 publication Critical patent/HUP0004363A2/hu
Publication of HUP0004363A3 publication Critical patent/HUP0004363A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány tárgya a leishmaniasis kezelésében orálisan alkalmazhatóúj szilárd gyógyszerkészítmények, az előállításukra szolgáló eljárásés egy ilyen készítményt tartalmazó gyógyszer-kombináció. A készítménymiltefosint, egy folyásszabályozó és/vagy csúsztatószert és egytöltőanyagot tartalmaz. Az eljárást az jellemzi, hogy (a) amiltefosint a folyásszabályozó szerrel, a töltőanyaggal és adottesetben további segédanyagokkal összekeverik, és (b) a kapottkeveréket kapszulákba vagy tasakokba töltik vagy tablettákkásajtolják. A kombináció a találmány szerinti szilárdgyógyszerkészítmény mellett egy hányás/émelygés elleni szert és/vagyegy hasmenéscsökkentő szert tartalmazhat. Ó
HU0004363A 1998-01-22 1998-01-22 Solid pharmaceutical compositions containing miltefosine for use in the treatment of leishmaniasis HUP0004363A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1998/000345 WO1999037289A1 (en) 1998-01-22 1998-01-22 Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis

Publications (2)

Publication Number Publication Date
HUP0004363A2 true HUP0004363A2 (hu) 2001-04-28
HUP0004363A3 HUP0004363A3 (en) 2002-12-28

Family

ID=8166843

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0004363A HUP0004363A3 (en) 1998-01-22 1998-01-22 Solid pharmaceutical compositions containing miltefosine for use in the treatment of leishmaniasis

Country Status (24)

Country Link
US (1) US6544551B1 (hu)
EP (1) EP1051159B1 (hu)
JP (1) JP2002501015A (hu)
KR (1) KR100517399B1 (hu)
CN (1) CN100413492C (hu)
AT (1) ATE215817T1 (hu)
AU (1) AU756805B2 (hu)
BR (1) BR9814772A (hu)
CA (1) CA2318260C (hu)
CZ (1) CZ299229B6 (hu)
DE (1) DE69804865T2 (hu)
DK (1) DK1051159T3 (hu)
ES (1) ES2175663T3 (hu)
HU (1) HUP0004363A3 (hu)
IL (1) IL136196A (hu)
NO (1) NO20003674L (hu)
NZ (1) NZ505648A (hu)
PL (1) PL189654B1 (hu)
PT (1) PT1051159E (hu)
SI (1) SI1051159T1 (hu)
SK (1) SK284839B6 (hu)
TR (1) TR200001717T2 (hu)
UA (1) UA68372C2 (hu)
WO (1) WO1999037289A1 (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7887817B2 (en) * 2002-01-25 2011-02-15 Aeterna Zentaris Gmbh Process for preventing protozoal diseases
DE10203195A1 (de) * 2002-01-25 2003-08-07 Zentaris Ag Verwendung von Alkylphosphocholinen in der Präventivbehandlung von Protozoenerkrankungen
AU2002346284A1 (en) * 2002-04-26 2003-11-10 Rudolf Perl Pharmaceutical compositions of phospholipid derivatives
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
AR040717A1 (es) * 2002-07-30 2005-04-20 Zentaris Ag Uso de alquilfosfocolinas en cominacion con medicamentos antitumorales para el tratamiento de oncosis maligna y benigna en seres humanos y animales
SI1663197T1 (sl) 2003-09-09 2008-06-30 Biogen Idec Internat Gmbh Uporaba derivatov fumarne kisline za zdravljenje sräśne insuficience in astme
ES2387192T3 (es) 2004-10-08 2012-09-17 Forward Pharma A/S Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico
US8703179B2 (en) 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
WO2010020276A1 (en) * 2008-08-19 2010-02-25 Orphanidis Pharma Research Gmbh Treatment of coccidian parasites
WO2011123691A1 (en) 2010-03-31 2011-10-06 Keryx Biopharmaceuticals, Inc. Perifosine and capecitabine as a combined treatment for cancer
US9358244B2 (en) 2010-11-22 2016-06-07 Oblita Therapeutics Bvba Solid dosage forms of oleyl phosphocholine
CA2840272C (en) 2011-06-24 2020-09-15 Glycoregimmune, Inc. Prevention and treatment of inflammatory conditions
US20160067269A1 (en) * 2013-04-08 2016-03-10 Academisch Ziekenhuis Leiden H.O.D.N. Miltefosin Or Perifosin For Use In The Treatment of IBD
AU2015316552C1 (en) 2014-09-17 2018-08-23 Steerlife India Private Limited Effervescent composition and method of making it
CN104473941A (zh) * 2014-12-20 2015-04-01 长沙佰顺生物科技有限公司 一种含有米替福新的药物制剂及其制备方法
US11219594B2 (en) 2015-12-12 2022-01-11 Steerlife India Private Limited Effervescent compositions of metformin and processes for preparation thereof
US20220183975A1 (en) * 2019-04-12 2022-06-16 Oblita Therapeutics Bvba Tablet dosage formulations of oleyl phosphocholine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE888444C (de) * 1951-11-10 1953-08-31 Benckiser Gmbh Joh A Verfahren zum Tablettieren von hygroskopischen Praeparaten
CA1338627C (en) * 1985-12-04 1996-10-01 Hansjorg Eibl Pharmaceuticals based on phosphoric acid esters for use in tumor therapy, and process for their preparation
US4762658A (en) * 1986-10-08 1988-08-09 Central Soya Company, Inc. Method of tableting of de-oiled phosphatides (lecithin)
EP0916343A1 (de) * 1989-09-27 1999-05-19 ASTA Medica Aktiengesellschaft Verwendung von Alkylphosphorsäure-Verbindungen zur Bekämpfung von Psoriasis-Erkrankungen
US5290769A (en) * 1989-09-27 1994-03-01 Asta Pharma Aktiengesellschaft Use of hexadecylphosphocholine for the treatment of psoriasis
DE4132344A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis

Also Published As

Publication number Publication date
BR9814772A (pt) 2000-10-24
DK1051159T3 (da) 2002-08-05
IL136196A (en) 2004-07-25
JP2002501015A (ja) 2002-01-15
KR20010034311A (ko) 2001-04-25
SK9862000A3 (en) 2000-11-07
WO1999037289A1 (en) 1999-07-29
NZ505648A (en) 2002-10-25
NO20003674D0 (no) 2000-07-18
CZ299229B6 (cs) 2008-05-21
IL136196A0 (en) 2001-05-20
SI1051159T1 (en) 2002-10-31
KR100517399B1 (ko) 2005-09-28
UA68372C2 (en) 2004-08-16
CA2318260A1 (en) 1999-07-29
SK284839B6 (sk) 2005-12-01
DE69804865D1 (de) 2002-05-16
ES2175663T3 (es) 2002-11-16
PL342838A1 (en) 2001-07-16
EP1051159B1 (en) 2002-04-10
AU756805B2 (en) 2003-01-23
CA2318260C (en) 2006-11-21
TR200001717T2 (tr) 2000-11-21
US6544551B1 (en) 2003-04-08
PL189654B1 (pl) 2005-09-30
EP1051159A1 (en) 2000-11-15
PT1051159E (pt) 2002-09-30
CN100413492C (zh) 2008-08-27
ATE215817T1 (de) 2002-04-15
DE69804865T2 (de) 2002-11-07
CN1283111A (zh) 2001-02-07
AU6212198A (en) 1999-08-09
HUP0004363A3 (en) 2002-12-28
NO20003674L (no) 2000-07-18
CZ20002596A3 (cs) 2000-10-11

Similar Documents

Publication Publication Date Title
HUP0004363A2 (hu) Miltefosint tartalmazó orális szilárd gyógyszerkészítmények leishmaniasis kezelésére
HUP0002316A2 (hu) Gyorsan olvadó orális adagolási formák
MXPA01004547A (es) Administracion oral de analogos de adenosina.
HUP9801615A2 (hu) Szimetikon/vízmentes kalcium-foszfát-kompozíciók
AU2431702A (en) Process for preparing pharmaceutical compositions for use with soft gelatin formulations
BG105173A (en) Novel salt form of pantoprazole
MY127350A (en) Flash-melt oral dose formulations
HUP0301390A2 (hu) Valzartánt tartalmazó orális gyógyászati készítmény
HUP0105481A2 (hu) Klaritromicint vagy származékait tartalmazó gyógyászati készítmények és eljárás előállításukra, valamint alkalmazásuk
GEP20043377B (en) Pharmaceutical Complex
UA66925C2 (uk) Поліморфні форми кристалічного цитрату азабіцикло[2.2.2]-октан-3-аміну, спосіб їх одержання, фармацевтична композиція та спосіб лікування блювання
HUP9902559A2 (hu) Paracetamolt és drotavenint tartalmazó gyógyszerkészítmény és eljárás előállítására
MY133368A (en) Process for preparing pharmaceutical compositions for use with soft gelatin formulations
BG104673A (en) Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
NO964775L (no) Fast farmasöytisk adenosinholdig preparat

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: ZENTARIS GMBH, DE

Free format text: FORMER OWNER(S): ASTA MEDICA AG., DE; ZENTARIS AG, DE; ZENTARIS GMBH, DE

FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished